2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide profile

2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide: a probe for bromo and extra C-terminal domain proteins; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	71271629
CHEMBL ID	2179387
CHEBI ID	95079
SCHEMBL ID	14721611
MeSH ID	M0581011

Synonym
QCR-192 ,
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide
1403764-72-6
pfi-1 (pf-6405761)
CHEMBL2179387 ,
bdbm50399434
pfi-1
HY-16586 ,
CS-1362
4E96
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzene-1-sulfonamide
gtpl7523
pf-6405761
S1216 ,
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfon amide
pf 06405761
pfi 1
SCHEMBL14721611
AC-32714
pf-06405761
AKOS024458163
FT-0696776
DTXSID90744264
EX-A480
CHEBI:95079
HMS3651E05
pfi1
pfi-1, >=98% (hplc)
pfi-1 (pf-06405761)
J-007379
NCGC00344624-13
SW219427-1
BCP07505
mfcd22580416
pfi-1(pf-6405761)
Q27088338
AS-16355
SB19334
HMS3426C13
CCG-268000
nsc777448
nsc-777448
2-methoxy-n-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide
nsc-768123
nsc768123
BP-25371
EN300-6493136
SY347010
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl)-bezenesulfonamide
Z1730011930

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
quinazolines	Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	23.9185	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	26.8370	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	26.8370	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	26.8370	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	26.8370	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	26.8370	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.2200	0.2200	0.2200	0.2200	AID977608
Chain A, Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.2200	0.2200	0.2200	0.2200	AID977608
Chain A, Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.2200	0.2200	0.2200	0.2200	AID977608
Chain A, Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.2200	0.2200	0.2200	0.2200	AID977608
Chain A, Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.2200	0.2200	0.2200	0.2200	AID977608
Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	0.8376	0.0004	0.4032	9.0500	AID1318693; AID1318694; AID1359304; AID1496253; AID1496414; AID1600709; AID1705258; AID1725318; AID1725319; AID1890889; AID1890890; AID710393; AID731808
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bromodomain-containing protein 4	Homo sapiens (human)	Kd	0.1360	0.0010	0.3691	8.9300	AID776067
CREB-binding protein	Homo sapiens (human)	Kd	49.0000	3.0840	6.3280	9.6000	AID710392
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin organization	Bromodomain-containing protein 4	Homo sapiens (human)
DNA damage response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
regulation of inflammatory response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Bromodomain-containing protein 4	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
response to hypoxia	CREB-binding protein	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
chromatin remodeling	CREB-binding protein	Homo sapiens (human)
regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
protein acetylation	CREB-binding protein	Homo sapiens (human)
signal transduction	CREB-binding protein	Homo sapiens (human)
canonical NF-kappaB signal transduction	CREB-binding protein	Homo sapiens (human)
regulation of smoothened signaling pathway	CREB-binding protein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase I	CREB-binding protein	Homo sapiens (human)
N-terminal peptidyl-lysine acetylation	CREB-binding protein	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
protein destabilization	CREB-binding protein	Homo sapiens (human)
cellular response to nutrient levels	CREB-binding protein	Homo sapiens (human)
cellular response to UV	CREB-binding protein	Homo sapiens (human)
homeostatic process	CREB-binding protein	Homo sapiens (human)
embryonic digit morphogenesis	CREB-binding protein	Homo sapiens (human)
positive regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
rhythmic process	CREB-binding protein	Homo sapiens (human)
protein-containing complex assembly	CREB-binding protein	Homo sapiens (human)
regulation of cellular response to heat	CREB-binding protein	Homo sapiens (human)
positive regulation of protein localization to nucleus	CREB-binding protein	Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombination	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Bromodomain-containing protein 4	Homo sapiens (human)
p53 binding	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin binding	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coregulator activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coactivator activity	Bromodomain-containing protein 4	Homo sapiens (human)
protein binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Bromodomain-containing protein 4	Homo sapiens (human)
enzyme binding	Bromodomain-containing protein 4	Homo sapiens (human)
lysine-acetylated histone binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II C-terminal domain binding	Bromodomain-containing protein 4	Homo sapiens (human)
P-TEFb complex binding	Bromodomain-containing protein 4	Homo sapiens (human)
histone reader activity	Bromodomain-containing protein 4	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
transcription coactivator binding	CREB-binding protein	Homo sapiens (human)
p53 binding	CREB-binding protein	Homo sapiens (human)
chromatin binding	CREB-binding protein	Homo sapiens (human)
damaged DNA binding	CREB-binding protein	Homo sapiens (human)
transcription coactivator activity	CREB-binding protein	Homo sapiens (human)
transcription corepressor activity	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
protein binding	CREB-binding protein	Homo sapiens (human)
zinc ion binding	CREB-binding protein	Homo sapiens (human)
acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
MRF binding	CREB-binding protein	Homo sapiens (human)
histone H3K18 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
histone H3K27 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
peptide-lysine-N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide lactyltransferase activity	CREB-binding protein	Homo sapiens (human)
DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
chromatin DNA binding	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
condensed nuclear chromosome	Bromodomain-containing protein 4	Homo sapiens (human)
nucleus	Bromodomain-containing protein 4	Homo sapiens (human)
nucleoplasm	Bromodomain-containing protein 4	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
nucleus	CREB-binding protein	Homo sapiens (human)
nucleoplasm	CREB-binding protein	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
cytosol	CREB-binding protein	Homo sapiens (human)
nuclear body	CREB-binding protein	Homo sapiens (human)
chromatin	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase complex	CREB-binding protein	Homo sapiens (human)
transcription regulator complex	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (194)

Assay ID	Title	Year	Journal	Article
AID1496459	Growth inhibition of human UACC257 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496525	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496530	Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496501	Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1890890	Displacement of biotinylated acetylated histone H4 peptide from human recombinant N-terminal GST-tagged BRD4 BD1 (49 to 170 residues) expressed in Escherichia coli expression system incubated for 30 mins by AlphaScreen assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.
AID710391	Binding affinity to CREBBP assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496432	Growth inhibition of human HOP62 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496493	Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1890891	Antiinflammatory activity against human THP-1 cells assessed as inhibition of LPS-induced IL-6 production incubated for 18 hrs by ELISA	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.
AID1725332	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell viability at 5 uM measured after 72 hrs by tryphan blue staining based assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1725337	Inhibition of BET in human MOLM-14 cells harboring FLT3-ITD mutant assessed as increase in HEXIM1 protein expression at 5 uM measured after 24 hrs by Western blot analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496445	Growth inhibition of human SW620 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496490	Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496500	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496458	Growth inhibition of human SK-MEL-5 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710380	Volume of distribution in rat at 1 mg/kg, iv	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725330	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell cycle arrest by measuring increase in cell population at sub-G1 phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID710381	Binding affinity to BAZ2B assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725326	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as cell cycle arrest by measuring decrease in cell population at S phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496428	Growth inhibition of human MOLT4 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725329	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell cycle arrest by measuring decrease in cell population at S phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496452	Growth inhibition of human LOXIMVI cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1705260	Antiproliferative activity against human HT29 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
AID1318696	Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
AID731808	Binding affinity to human BRD4 bromodomain 1 using H4Ac4 peptide by amplified luminescent proximity homogeneous assay	2013	Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8	Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
AID1890889	Displacement of acetylated histone H4 peptide from His-tagged recombinant human BRD4 expressed in bacteria by AlphaScreen assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.
AID1496524	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496528	Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496431	Growth inhibition of human A549/ATCC cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496485	Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496508	Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1850140	Antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1496539	Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496429	Growth inhibition of human RPMI8226 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496538	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496496	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1318694	Inhibition of human BRD4 BD2 (342 to 460 residues) at 30 uM preincubated for 30 mins followed by substrate addition measured after 30 mins by TR-FRET assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
AID1725316	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as metabolic activity at 1 uM measured after 72 hrs by MTT assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496488	Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496534	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725323	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as reduction in cell proliferation at 1 to 5 uM after 72 hrs by tryphan blue staining based assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496453	Growth inhibition of human MALME-3M cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496510	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496253	Inhibition of BRD4 (unknown origin)	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1725321	Binding affinity to N-terminal His-tagged human recombinant BRD4 bromodomain 1 (44-170 residues) expressed in Escherichia coli assessed as change in melting temperature at 10 uM by BromoMELT assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496506	Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496475	Growth inhibition of human UO31 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1318697	Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
AID1496492	Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496430	Growth inhibition of human SR cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496491	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496419	Growth inhibition of human A498 cells after 48 hrs by SRB assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496426	Growth inhibition of human HL-60(TB) cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496447	Growth inhibition of human SF295 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496522	Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496427	Growth inhibition of human K562 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496439	Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1705259	Antiproliferative activity against human HL60 cells incubated for 72 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
AID1496457	Growth inhibition of human SK-MEL-28 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496503	Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496499	Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496434	Growth inhibition of human NCI-H226 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496451	Growth inhibition of human U251 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496425	Growth inhibition of human CCRF-CEM cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496450	Growth inhibition of human SNB75 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496471	Growth inhibition of human CAKI-1 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496516	Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710384	Binding affinity to BRDT isoform 1 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID710383	Binding affinity to pb1 isoform 5 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725328	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell cycle arrest by measuring increase in cell population at G0/G1 phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID710314	Drug concentration in rat gut at 1 mg/kg, iv measured 7 hrs post dose	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496497	Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496531	Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496515	Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496420	Growth inhibition of human HT-29 cells after 48 hrs by SRB assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496512	Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496513	Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710311	Half life in mouse at 2 mg/kg, sc	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496468	Growth inhibition of human 786-0 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496464	Growth inhibition of human OVCAR5 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496532	Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496463	Growth inhibition of human OVCAR4 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710393	Inhibition of BRD4 isoform 1 by AlphaScreen assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725331	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as cell viability at 5 uM measured after 72 hrs by tryphan blue staining based assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1850138	Antibacterial activity against Bacillus subtilis 168 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two-fold serial dilution assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1496446	Growth inhibition of human SF268 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496520	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710386	Binding affinity to BRD3 isoform 2 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496476	Growth inhibition of human PC3 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1318695	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
AID1496460	Growth inhibition of human UACC62 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710318	Plasma clearance in rat at 1 mg/kg, iv	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496514	Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496462	Growth inhibition of human OVCAR3 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496474	Growth inhibition of human TK10 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496526	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496461	Growth inhibition of human IGROV1 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496533	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710315	Oral bioavailability clearance in rat at 2 mg/kg	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496438	Growth inhibition of human NCI-H522 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496517	Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710388	Binding affinity to BRD3 isoform 1 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496498	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496443	Growth inhibition of human HT-29 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496521	Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496465	Growth inhibition of human OVCAR8 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496505	Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496473	Growth inhibition of human SN12C cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1705261	Antiproliferative activity against human WI-38 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
AID1725317	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as metabolic activity at 1 uM measured after 72 hrs by MTT assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1725350	Cytotoxicity against human PBMC assessed as reduction in colony formation at 1 to 5 uM measured after 7 to 11 days	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496487	Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496437	Growth inhibition of human NCI-H460 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496509	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725320	Binding affinity to N-terminal His-tagged human recombinant BRD2 bromodomain 1 (71 to 194 residues) expressed in Escherichia coli assessed as change in melting temperature at 10 uM by BromoMELT assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496456	Growth inhibition of human SK-MEL-2 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496502	Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496466	Growth inhibition of human NCI-ADR-RES cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725340	Anticlonogenic activity against AML patient derived BMMC harboring FLT3-ITD/FLT3-TKD mutant assessed as reduction in colony formation at 1 to 5 uM measured after 7 to 11 days	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496481	Growth inhibition of human BT549 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710382	Binding affinity to PCAF assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID710392	Binding affinity to CREBBP by SPR method	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496469	Growth inhibition of human A498 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496479	Growth inhibition of human MDA-MB-231 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496483	Growth inhibition of human MDA-MB-468 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496523	Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725322	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as reduction in cell proliferation at 1 to 5 uM after 72 hrs by tryphan blue staining based assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID710310	Tmax in mouse at 2 mg/kg, sc	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496527	Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496449	Growth inhibition of human SNB19 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710387	Binding affinity to BRD4 isoform 1 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496448	Growth inhibition of human SF539 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496477	Growth inhibition of human DU145 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710312	Cmax in mouse at 2 mg/kg, sc	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725325	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as cell cycle arrest by measuring increase in cell population at G0/G1 phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID710317	Half life in rat at 1 mg/kg, iv	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1409977	Oral bioavailability in rat	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
AID1496536	Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496484	Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496435	Growth inhibition of human NCI-H23 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496467	Growth inhibition of human SKOV3 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496504	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725336	Inhibition of BET in human HEL cells harboring JAK2 V617F mutant assessed as increase in HEXIM1 protein expression at 5 uM measured after 24 hrs by Western blot analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID710389	Binding affinity to BRD2 isoform 2 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1725346	Inhibition of BET in human K562 cells harboring BCR-ABL assessed as increase in HEXIM1 protein expression at 5 uM measured after 24 to 48 hrs by Western blot analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496436	Growth inhibition of human NCI-H322M cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496455	Growth inhibition of human MDA-MB-435 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725327	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as cell cycle arrest by measuring increase in cell population at sub-G1 phase at 1 to 5 uM measured after 24 hrs by propidium iodide staining based FACS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496414	Inhibition of recombinant His-tagged human BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by H4K5acK8acK12acK16ac substrate addition measured after 30 mins by AlphaScreen assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725318	Inhibition of BRD4 in human HEL cells harboring JAK2 V617F mutant assessed as decrease in metabolic activity measured after 72 hrs by MTT assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1705257	Inhibition of BRD4 BD1 (unknown origin) at 1 uM preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay relative to control	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
AID1496482	Growth inhibition of human T47D cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1600709	Inhibition of BRD4 bromodomain (unknown origin)	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
AID1850139	Antibacterial activity against Staphylococcus aureus 29213 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1318693	Inhibition of human His-tagged BRD4 BD1 (49 to 170 residues) using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by TR-FRET assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
AID710390	Binding affinity to BRD2 isoform 1 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496519	Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496478	Growth inhibition of human MCF7 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710316	Half life in rat liver microsomes	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496480	Growth inhibition of human Hs 578T cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1359304	Inhibition of BRD4 (unknown origin) by Alphascreen assay	2018	European journal of medicinal chemistry, May-25, Volume: 152	Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
AID1496440	Growth inhibition of human HCC2998 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496454	Growth inhibition of human M14 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496535	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496494	Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496507	Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496444	Growth inhibition of human KM12 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710385	Binding affinity to BRD4 isoform 2 assessed as change in melting temperature at 10 uM by thermal shift assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID776067	Binding affinity to first bromodomain of BRD4 (unknown origin)	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.
AID1496489	Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1845926	Reversal of HIV-1 latency infected in GFP-fused human J-Lat C11 cells assessed as increase in GFP expression at 10 uM incubated for 72 hrs by flow cytometry	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	HIV latency reversal agents: A potential path for functional cure?
AID1496529	Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496441	Growth inhibition of human HCT116 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496442	Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496537	Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496433	Growth inhibition of human HOP92 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496495	Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496470	Growth inhibition of human ACHN cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID710313	Protein binding in rat plasma	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID710394	Inhibition of LPS-induced IL6 production in human PBMC by ELISA	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1496518	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1496486	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725319	Inhibition of BRD4 in human MOLM-14 cells harboring FLT3-ITD mutant assessed as decrease in metabolic activity measured after 72 hrs by MTT assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1496472	Growth inhibition of human RXF393 cells at 10 uM after 48 hrs by sulforhodamine B assay relative to control	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1725351	Cytotoxicity against human CD34+ cells assessed as reduction in colony formation at 1 to 5 uM measured after 7 to 11 days	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies.
AID1705258	Inhibition of BRD4 BD1 (unknown origin) preincubated for 15 mins followed by peptide addition and measured after 60 mins by TR-FRET assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
AID1496421	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
AID1345665	Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	10 (58.82)	24.3611
2020's	7 (41.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.88%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (94.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.17	1	aromatic ether; nitrile; polyether; tertiary amino compound
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.	3.41	1	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.41	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	2.41	1	penicillin allergen; penicillin	antibacterial drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.41	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
indolactam v indolactam V: only the (-)-isomer of indolactam V showed carcinogenic activity; structure given in first source	3.41	1	indoles
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.41	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
12-deoxyphorbol 13-acetate [no description available]	3.41	1	phorbol ester	metabolite
3-(2-Methyl-1,3-thiazol-4-yl)aniline [no description available]	2.17	1	substituted aniline
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	2.17	1	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
belinostat [no description available]	3.41	1	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	3.41	1	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide [no description available]	3.41	1
cp 91149 CP 91149: inhibits liver glycogen phosphorylase; structure in first source	2.41	1
cp-673,451 CP-673,451: is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase; structure in first source	2.41	1	aminoquinoline
cl 075 [no description available]	3.41	1
bi 2536 [no description available]	3.41	1
az 505 AZ 505: an SMYD2 inhibitor; structure in first source	3.41	1
pc190723 PC190723: Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source	2.41	1
pf-04691502 [no description available]	2.41	1
bix 01294 [no description available]	3.41	1	piperidines
pf 04929113 [no description available]	2.41	1
unc 0638 UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source	3.41	1	quinazolines
jq1 compound [no description available]	4.79	8	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.83	3	benzodiazepine
pf-4708671 [no description available]	2.41	1
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.52	2	imidazoquinoline
pf-5274857 1-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source	2.41	1
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	2.17	1	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
epz-6438 tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity	3.41	1
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	3.41	1	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	3.99	3

Condition	Relationship Strength	Studies
Leucocythaemia [description not available]	2.21	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
HIV Coinfection [description not available]	3.23	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.23	1

2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide

Description

Cross-References

Synonyms (50)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (76)

Molecular Functions (44)

Ceullar Components (27)

Bioassays (194)

Research

Studies (17)

Market Indicators

Research Demand Index: 11.69

Study Types

2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide

Description

Cross-References

Synonyms (50)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (76)

Molecular Functions (44)

Ceullar Components (27)

Bioassays (194)

Research

Studies (17)

Market Indicators

Research Demand Index: 11.69

Study Types

Related Drugs (32)

Related Conditions (7)